silibinin inhibits hiv-1 infection by reducing cellular activation and proliferationsilibinin抑制hiv - 1感染通过减少细胞的激活和增殖.pdfVIP

Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation 1 1 6 5 1 Janela McClure , Erica S. Lovelace , Shokrollah Elahi , Nicholas J. Maurice , Jessica Wagoner , 1 4 6 3,6 6 Joan Dragavon , John E. Mittler , Zane Kraft , Leonidis Stamatatos , Helen Horton , Stephen C. De Rosa1,5, Robert W. Coombs1,2, Stephen J. Polyak1,3,4* 1 Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America, 2 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 3 Department of Global Health, University of Washington, Seattle, Washington, United States of America, 4 Department of Microbiology, University of Washington, Seattle, Washington, United States of America, 5 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 6 Viral Vaccines Program, Seattle Biomed, Seattle, Washington, United States of America Abstract Purified silymarin-derived natural products from the milk thistle plant (Silybum marianum) block hepatitis C virus (HCV) infection and inhibit T cell proliferation in vitro. An intravenous formulation of silibinin (SIL), a major component of silymarin, displays anti-HCV effects in humans and also inhibits T-cell proliferation in vitro. We show that SIL inhibited replication of HIV-1 in TZM-bl cells, PBMCs, and CEM cells in vitro. SIL suppression of HIV-1 coincided with dose-dependent reductions in actively proliferating CD19+, CD4+, and CD8+ cells, resulting in fewer CD4+ T cells expres